DWP 431
Alternative Names: Bongros-BMP; Bongros/BMP-2; DWP-431; Novosis; NOVOSIS-Dental; rhBMP-2Latest Information Update: 28 Jan 2026
At a glance
- Originator Daewoong Pharmaceutical
- Developer Daewoong Pharmaceutical; HanAll Biopharma
- Class Proteins
- Mechanism of Action Bone morphogenetic protein 2 stimulants; Osteogenesis stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alveolar bone loss; Spinal disorders
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Spinal-disorders in USA
- 03 Dec 2021 Preclinical trials in Spinal disorders in USA (unspecified route), prior to December 2021 (Daewoong Pharmaceutical pipeline, December 2021)
- 12 May 2015 Phase III development is ongoing for Spinal disorders in South Korea